Side-by-side · Research reference
5-Amino-1MQvsHexarelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongDraft8/38 cited
BPhase 1Reviewed19/45 cited
5-Amino-1MQ
NNMT inhibitor · Methylation / SAM modulation
Oral · Once daily fasted
Hexarelin
Hexapeptide GHRP · Cardio-tropic
SQ · Multiple sites · 1–3×/day
01Mechanism of Action
Parameter
5-Amino-1MQ
Hexarelin
Primary target
Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018
Ghrelin receptor (GHS-R1a) + cardiac CD36Smith 1996Ghigo 1997
Pathway
NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018
GHS-R1a → Gαq → Ca²⁺ → GH release. CD36 engagement → direct cardio-tropic actionGhigo 1997
Downstream effect
Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018
Strong GH pulse + IGF-1 elevation; cardio-protective effects in animal MI modelsGhigo 1997
Origin
Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018
Synthetic hexapeptide His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂Smith 1996
Antibody development
—
—
02Dosage Protocols
Parameter
5-Amino-1MQ
Hexarelin
Standard dose
100–200 mg / day oralNeelakantan 2018
Anecdotal community range; murine doses scaled.
100–200 mcg per injectionSmith 1996
Frequency
Once daily, fasted
1–2× per day max (tachyphylaxis with chronic 3× daily)
Lower / starter dose
50 mg / day
50 mcg per dose
Evidence basis
Animal-strong; no human RCT dataNeelakantan 2018
Phase 1 / Phase 2 trialsSmith 1996Ghigo 1997
Duration
8–12 weeks per cycle
4–8 weeks on / 4–8 weeks off (tachyphylaxis mitigation)
Form
Oral capsule
—
Timing
Morning fasted preferred
Pre-sleep + fasted preferred
Reconstitution
—
Bacteriostatic water
04Side Effects & Safety
Parameter
5-Amino-1MQ
Hexarelin
GI symptoms
Mild nausea (anecdotal)
—
Methylation disruption
Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)
—
Long-term safety
Unknown — no human trials
—
Cancer risk
Unclear — NNMT also studied in oncology contexts
Contraindicated in active malignancy (GH/IGF-1 axis)
Pregnancy / OB
Avoid
Avoid
Drug interactions
Theoretical with niacin / B-vitamin supplements
—
Hunger
—
Strong appetite increase via ghrelin agonism
IGF-1 elevation
—
Strong; monitor with chronic high-dose use
Absolute Contraindications
5-Amino-1MQ
- ·Pregnancy / breastfeeding
- ·Active malignancy
Hexarelin
- ·Active malignancy
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
Relative Contraindications
5-Amino-1MQ
- ·Methylation-sensitive conditions (MTHFR mutation)
- ·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)
Hexarelin
- ·Untreated diabetes
- ·Severe hyperprolactinemia
05Administration Protocol
Parameter
5-Amino-1MQ
Hexarelin
1. Form
Oral capsule. No injection.
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.
2. Administration
Take with water, fasted preferred.
SQ — abdomen or thigh. Rotate sites.
3. Timing
Morning fasted.
Pre-sleep + fasted preferred. Cycle on/off to avoid tachyphylaxis.
4. Storage
Room temp ≤25 °C, dry place.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Caveat
Monitor B-vitamin status with chronic use.
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
5-Amino-1MQ
— no documented stacks
Hexarelin
+ CJC-1295 (no DAC)
StrongHexarelin (GHRP) + CJC-1295-no-DAC (GHRH analogue) is the higher-amplitude variant of the standard GHRH+GHRP stack. Hexarelin produces a stronger pulse than ipamorelin but with cortisol + prolactin signal — choose this stack for maximum GH amplitude when side-effect tolerance is acceptable. Cycle aggressively.
- Hexarelin
- 100 mcg SQ · pre-sleep
- CJC-1295 (no DAC)
- 100 mcg SQ · same injection
- Primary benefit
- Maximum GH pulse amplitude (with side-effect signal)